Postauthorization safety study of the DPP-4 inhibitor saxagliptin: a large-scale multinational family of cohort studies of five outcomes

Jul-17

AUTHORS : Dr Vincent Lo Re III, Center for Clinical Epidemiology and Biostatistics, 836 Blockley Hall, 423 Guardian Drive, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104-6021, USA – Email: vincentl@mail.med.upenn.edu – Profile: https://www.med.upenn.edu/apps/faculty/index.php/g275/p6951

JOURNAL : BMJ Open Diabetes Research & Care

REFERENCE: 5(1):e000400

DOI : 10.1136/bmjdrc-2017-000400

Postauthorization safety study of the DPP-4 inhibitor saxagliptin: a large-scale multinational family of cohort studies of five outcomes

More publications

Comparative effect of aspirin versus clopidogrel monotherapy on incident type 2 diabetes in patients with atherosclerotic cardiovascular diseases: A target trial emulation study

Postoperative Weight Loss After Antiobesity Medications and Revision Risk After Joint Replacement

Comparative effectiveness and prescribing trends of modified release versus immediate release indapamide in patients with hypertension: cohort study